Fosphenytoin sodium (BioDeep_00000732723)
代谢物信息卡片
Fosphenytoin (disodium)
化学式: C16H13N2Na2O6P (406.0306608)
中文名称: 苯妥英钠盐
谱图信息:
最多检出来源 () 0%
分子结构信息
SMILES: C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)([O-])[O-])C3=CC=CC=C3.[Na+].[Na+]
InChI: /q
描述信息
C78272 - Agent Affecting Nervous System > C264 - Anticonvulsant Agent
D002491 - Central Nervous System Agents > D000927 - Anticonvulsants
D002317 - Cardiovascular Agents > D026941 - Sodium Channel Blockers
D049990 - Membrane Transport Modulators
同义名列表
2 个代谢物同义名
数据库引用编号
分类词条
相关代谢途径
Reactome(0)
BioCyc(0)
PlantCyc(0)
代谢反应
0 个相关的代谢反应过程信息。
Reactome(0)
BioCyc(0)
WikiPathways(0)
Plant Reactome(0)
INOH(0)
PlantCyc(0)
COVID-19 Disease Map(0)
PathBank(0)
PharmGKB(0)
0 个相关的物种来源信息
在这里通过桑基图来展示出与当前的这个代谢物在我们的BioDeep知识库中具有相关联信息的其他代谢物。在这里进行关联的信息来源主要有：
- PubMed: 来源于PubMed文献库中的文献信息，我们通过自然语言数据挖掘得到的在同一篇文献中被同时提及的相关代谢物列表，这个列表按照代谢物同时出现的文献数量降序排序，取前10个代谢物作为相关研究中关联性很高的代谢物集合展示在桑基图中。
- NCBI Taxonomy: 通过文献数据挖掘，得到的代谢物物种来源信息关联。这个关联信息同样按照出现的次数降序排序，取前10个代谢物作为高关联度的代谢物集合展示在桑吉图上。
- Chemical Taxonomy: 在物质分类上处于同一个分类集合中的其他代谢物
- Chemical Reaction: 在化学反应过程中，存在为当前代谢物相关联的生化反应过程中的反应底物或者反应产物的关联代谢物信息。
点击图上的相关代谢物的名称，可以跳转到相关代谢物的信息页面。
文献列表
- Shusaku Noro, Yoshinobu Seo, Kaori Honjo, Masahiro Okuma, Bunsho Asayama, Yuki Amano, Masanori Kyono, Kazuya Sako, Hirohiko Nakamura. Intravenous fosphenytoin therapy for rescue of acute trigeminal neuralgia crisis in patients awaiting neurosurgical procedures: A cross-sectional study.
Journal of clinical neuroscience : official journal of the Neurosurgical Society of Australasia.
2021 Dec; 94(?):59-64. doi:
10.1016/j.jocn.2021.09.040. [PMID: 34863463] - Abhishek G Sathe, Usha Mishra, Vijay Ivaturi, Richard C Brundage, James C Cloyd, Jordan J Elm, James M Chamberlain, Robert Silbergleit, Jaideep Kapur, Daniel H Lowenstein, Shlomo Shinnar, Hannah R Cock, Nathan B Fountain, Lynn Babcock, Lisa D Coles. Early Exposure of Fosphenytoin, Levetiracetam, and Valproic Acid After High-Dose Intravenous Administration in Young Children With Benzodiazepine-Refractory Status Epilepticus.
Journal of clinical pharmacology.
2021 06; 61(6):763-768. doi:
10.1002/jcph.1801. [PMID: 33336359] - S Nishida, Y Hayashi, K Hirai, A Takekoshi, Y Yamada, R Kobayashi, S Shimizu, T Niwa, H Hayashi, T Shimohata, T Sugiyama, A Suzuki. Effect of therapeutic plasma exchange on phenytoin plasma concentration in patients receiving intravenous fosphenytoin therapy.
Die Pharmazie.
2020 10; 75(10):488-490. doi:
10.1691/ph.2020.0525. [PMID: 33305722] - Kavita Srivastava, Shirish Bhartiya, Vrushabh Gavli, Rahul Patil, Surekha Rajadhyaksha. Efficacy, Tolerability and Serum Phenytoin Levels after Intravenous Fosphenytoin Loading Dose in Children with Status Epilepticus.
Indian pediatrics.
2020 03; 57(3):218-221. doi:
10.1007/s13312-020-1754-5. [PMID: 32198860] - Kanae Higuchi, Daiki Yamashita, Yushi Kashihara, Makoto Kakara, Takeshi Hirota, Masaaki Hirakawa, Ichiro Ieiri. Population Pharmacokinetic Analysis of Phenytoin After Intravenous Administration of Fosphenytoin in Adult and Elderly Epileptic Patients.
Therapeutic drug monitoring.
2019 10; 41(5):674-680. doi:
10.1097/ftd.0000000000000651. [PMID: 31095070] - Yuta Ohno, Takashi Niwa, Keita Hirai, Keiko Suzuki, Yuto Yamada, Yuichi Hayashi, Hideki Hayashi, Akio Suzuki, Yoshinori Itoh. Time-Dependent Decline in Serum Phenytoin Concentration With Heightened Convulsive Seizure Risk by Prolonged Administration of Fosphenytoin in Japanese: A Retrospective Study.
Therapeutic drug monitoring.
2018 08; 40(4):507-511. doi:
10.1097/ftd.0000000000000521. [PMID: 29683874] - Brady S Moffett, Mindl M Weingarten, Lindsay R Schmees, Marianne Galati, Jennifer Erklauer, James J Riviello. Fosphenytoin Population Pharmacokinetics in the Acutely Ill Pediatric Population.
Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.
2018 08; 19(8):748-754. doi:
10.1097/pcc.0000000000001627. [PMID: 29927880] - Ashley B Prusakov, Anup D Patel, Justin W Cole. Impact of Obesity on Fosphenytoin Volume of Distribution in Pediatric Patients.
Journal of child neurology.
2018 07; 33(8):534-536. doi:
10.1177/0883073818770801. [PMID: 29714095] - L Vrignaud, C Simon, M-S Agier, T Bejan-Angoulvant, E Bouquet, F Beau-Salinas, A-P Jonville-Béra. [Drugs news].
Archives de pediatrie : organe officiel de la Societe francaise de pediatrie.
2017 Aug; 24(8):783-787. doi:
10.1016/j.arcped.2017.05.008. [PMID: 28668216] - Mindl M Messinger, Brady S Moffett, Angus Wilfong. Impact of Body Habitus on Phenytoin Levels Following Fosphenytoin Loading Dose in Pediatric Patients.
Therapeutic drug monitoring.
2015 Dec; 37(6):772-5. doi:
10.1097/ftd.0000000000000241. [PMID: 26402424] - Dong Wook Kim, Tae-Eun Kim, Misuk Ji, Young Il Chun. Safety, Tolerability, and Pharmacokinetics of Fosphenytoin Loading in Patients With Subarachnoid Hemorrhage.
Clinical neuropharmacology.
2015 Nov; 38(6):248-51. doi:
10.1097/wnf.0000000000000112. [PMID: 26536021] - Edward E Patterson, Ilo E Leppik, Lisa D Coles, Michael Podell, Charles H Vite, William Bush, James C Cloyd. Canine status epilepticus treated with fosphenytoin: A proof of principle study.
Epilepsia.
2015 Jun; 56(6):882-7. doi:
10.1111/epi.12994. [PMID: 25953073] - Lisa D Coles, Ilo E Leppik, Edward E Patterson, Zachary Rivers, Usha Mishra, James C Cloyd. Use of IV fosphenytoin pharmacokinetics to determine the loading dose for a clinical trial of canine status epilepticus.
Epilepsia.
2015 Jun; 56(6):888-94. doi:
10.1111/epi.12961. [PMID: 25952988] - Kevin A Kaucher, Nicole M Acquisto, Gauri G Rao, David C Kaufman, Jeff D Huntress, Alan Forrest, Curtis E Haas. Relative bioavailability of orally administered fosphenytoin sodium injection compared with phenytoin sodium injection in healthy volunteers.
Pharmacotherapy.
2015 May; 35(5):482-8. doi:
10.1002/phar.1589. [PMID: 26011141] - Monika Popławska, Kinga K Borowicz, Stanisław J Czuczwar. The safety and efficacy of fosphenytoin for the treatment of status epilepticus.
Expert review of neurotherapeutics.
2015; 15(9):983-92. doi:
10.1586/14737175.2015.1074523. [PMID: 26289487] - Matthew B Jensen, Ahsan Sattar, Khalid Al Sherbini. Survey of prophylactic antiseizure drug use for non-traumatic intracerebral hemorrhage.
Neurological research.
2013 Nov; 35(9):984-7. doi:
10.1179/1743132813y.0000000197. [PMID: 23582711] - Yushi Inoue, Naotaka Usui, Tadayuki Hiroki, Kenji Shimizu, Susumu Kobayashi, Shigeki Shimasaki. Bioavailability of intravenous fosphenytoin sodium in healthy Japanese volunteers.
European journal of drug metabolism and pharmacokinetics.
2013 Jun; 38(2):139-48. doi:
10.1007/s13318-012-0105-x. [PMID: 22968854] - Jun Tanaka, Hidefumi Kasai, Kenji Shimizu, Shigeki Shimasaki, Yuji Kumagai. Population pharmacokinetics of phenytoin after intravenous administration of fosphenytoin sodium in pediatric patients, adult patients, and healthy volunteers.
European journal of clinical pharmacology.
2013 Mar; 69(3):489-97. doi:
10.1007/s00228-012-1373-8. [PMID: 22918614] - Haodan Yuan, Na Li, Yurong Lai. Evaluation of in vitro models for screening alkaline phosphatase-mediated bioconversion of phosphate ester prodrugs.
Drug metabolism and disposition: the biological fate of chemicals.
2009 Jul; 37(7):1443-7. doi:
10.1124/dmd.108.026245. [PMID: 19372225] - Marc P DiFazio, Loranee Braun, Scott Freedman, Patrick Hickey. Rotavirus-induced seizures in childhood.
Journal of child neurology.
2007 Dec; 22(12):1367-70. doi:
10.1177/0883073807307083. [PMID: 18174553] - Kevin D McBryde, Jennifer Wilcox, Kanwal K Kher. Hyperphosphatemia due to fosphenytoin in a pediatric ESRD patient.
Pediatric nephrology (Berlin, Germany).
2005 Aug; 20(8):1182-5. doi:
10.1007/s00467-005-1947-0. [PMID: 15965770] - NULL. Clinical policy: Critical issues in the evaluation and management of adult patients presenting to the emergency department with seizures.
Annals of emergency medicine.
2004 May; 43(5):605-25. doi:
10.1016/s019606440400068x. [PMID: 15111920] - Xiaolan Wang, Philip N Patsalos. A comparison of central brain (cerebrospinal and extracellular fluids) and peripheral blood kinetics of phenytoin after intravenous phenytoin and fosphenytoin.
Seizure.
2003 Sep; 12(6):330-6. doi:
10.1016/s1059-1311(03)00099-2. [PMID: 12915078] - Bernhards R Ogutu, Charles R J C Newton, Simon N Muchohi, Godfrey O Otieno, Geoffrey Edwards, William M Watkins, Gilbert O Kokwaro. Pharmacokinetics and clinical effects of phenytoin and fosphenytoin in children with severe malaria and status epilepticus.
British journal of clinical pharmacology.
2003 Jul; 56(1):112-9. doi:
10.1046/j.1365-2125.2003.01829.x. [PMID: 12848783] - Tycho Heimbach, Doo-Man Oh, Lilian Y Li, Markus Forsberg, Jouko Savolainen, Jukka Leppänen, Yasushi Matsunaga, Gordon Flynn, David Fleisher. Absorption rate limit considerations for oral phosphate prodrugs.
Pharmaceutical research.
2003 Jun; 20(6):848-56. doi:
10.1023/a:1023827017224. [PMID: 12817887] - James H Fischer, Tejal V Patel, Patricia A Fischer. Fosphenytoin: clinical pharmacokinetics and comparative advantages in the acute treatment of seizures.
Clinical pharmacokinetics.
2003; 42(1):33-58. doi:
10.2165/00003088-200342010-00002. [PMID: 12489978] - Bernhards R Ogutu, Charles R J C Newton, Simon N Muchohi, Godfrey O Otieno, Gilbert O Kokwaro. Phenytoin pharmacokinetics and clinical effects in African children following fosphenytoin and chloramphenicol coadministration.
British journal of clinical pharmacology.
2002 Dec; 54(6):635-42. doi:
10.1046/j.1365-2125.2002.01689.x. [PMID: 12492612] - Mark T Keegan, Lois R Bondy, Joseph L Blackshear, William L Lanier. Hypocalcemia-like electrocardiographic changes after administration of intravenous fosphenytoin.
Mayo Clinic proceedings.
2002 Jun; 77(6):584-6. doi:
10.4065/77.6.584. [PMID: 12059129] - S N Muchohi, G O Kokwaro, T E Maitho, R W Munenge, W M Watkins, G Edwards. Pharmacokinetics of phenytoin following intravenous and intramuscular administration of fosphenytoin and phenytoin sodium in the rabbit.
European journal of drug metabolism and pharmacokinetics.
2002 Apr; 27(2):83-9. doi:
10.1007/bf03190421. [PMID: 12064376] - T M Annesley, S Kurzyniec, G D Nordblom, N Buchanan, W Pool, M Reily, R Talaat, W L Roberts. Glucuronidation of prodrug reactive site: isolation and characterization of oxymethylglucuronide metabolite of fosphenytoin.
Clinical chemistry.
2001 May; 47(5):910-8. doi:
10.1093/clinchem/47.5.910. [PMID: 11325896] - F M Pryor, B Gidal, R E Ramsay, J DeToledo, R O Morgan. Fosphenytoin: pharmacokinetics and tolerance of intramuscular loading doses.
Epilepsia.
2001 Feb; 42(2):245-50. doi:
10.1046/j.1528-1157.2001.4220245.x. [PMID: 11240597] - A Dasgupta, E Schlette. Rapid in vitro conversion of fosphenytoin into phenytoin in sera of patients with liver disease: role of alkaline phosphatase.
Journal of clinical laboratory analysis.
2001; 15(5):244-50. doi:
10.1002/jcla.1035. [PMID: 11574952] - Y Yoon, A Jagoda. New antiepileptic drugs and preparations.
Emergency medicine clinics of North America.
2000 Nov; 18(4):755-65. doi:
10.1016/s0733-8627(05)70157-7. [PMID: 11130937] - A Dasgupta, B C Handy, P Datta. Mathematical models to calculate fosphenytoin concentrations in the presence of phenytoin using phenytoin immunoassays and alkaline phosphatase.
American journal of clinical pathology.
2000 Jan; 113(1):87-92. doi:
10.1309/te4w-938m-urp2-bmeq. [PMID: 10631861] - F T Aweeka, M D Gottwald, J G Gambertoglio, T L Wright, T D Boyer, A S Pollock, M A Eldon, A R Kugler, B K Alldredge. Pharmacokinetics of fosphenytoin in patients with hepatic or renal disease.
Epilepsia.
1999 Jun; 40(6):777-82. doi:
10.1111/j.1528-1157.1999.tb00778.x. [PMID: 10368078] - W L Roberts, B K De, J P Coleman, T M Annesley. Falsely increased immunoassay measurements of total and unbound phenytoin in critically ill uremic patients receiving fosphenytoin.
Clinical chemistry.
1999 Jun; 45(6 Pt 1):829-37. doi:
. [PMID: 10351992] - A Dasgupta, B F Warner, P Datta. Use of alkaline phosphatase to correct the underestimation of fosphenytoin concentration in serum measured by phenytoin immunoassays.
American journal of clinical pathology.
1999 Apr; 111(4):557-62. doi:
10.1093/ajcp/111.4.557. [PMID: 10191778] - A H Burstein, D S Cox, B Mistry, N D Eddington. Phenytoin pharmacokinetics following oral administration of phenytoin suspension and fosphenytoin solution to rats.
Epilepsy research.
1999 Apr; 34(2-3):129-33. doi:
10.1016/s0920-1211(98)00107-7. [PMID: 10210027] - D Manca, R M Walker, G Krishna, M J Graziano, M L Kropko. Probabilistic approach to the establishment of maximal content limits of impurities in drug formulations: the case of parenteral diphenylhydantoic acid.
Regulatory toxicology and pharmacology : RTP.
1999 Feb; 29(1):1-14. doi:
10.1006/rtph.1998.1275. [PMID: 10051414] - N Y Walton, B M Uthman, K El Yafi, J M Kim, D M Treiman. Phenytoin penetration into brain after administration of phenytoin or fosphenytoin.
Epilepsia.
1999 Feb; 40(2):153-6. doi:
10.1111/j.1528-1157.1999.tb02068.x. [PMID: 9952260] - A Dasgupta, D Havlik. Elevated free fosphenytoin concentrations in uremic sera: uremic toxins hippuric acid and indoxyl sulfate do not account for the impaired protein binding of fosphenytoin.
Therapeutic drug monitoring.
1998 Dec; 20(6):658-62. doi:
10.1097/00007691-199812000-00013. [PMID: 9853983] - M Takeoka, K S Krishnamoorthy, T B Soman, V S Caviness. Fosphenytoin in infants.
Journal of child neurology.
1998 Nov; 13(11):537-40. doi:
10.1177/088307389801301102. [PMID: 9853645] - L E Knapp, A R Kugler. Clinical experience with fosphenytoin in adults: pharmacokinetics, safety, and efficacy.
Journal of child neurology.
1998 Oct; 13 Suppl 1(?):S15-8; discussion S30. doi:
10.1177/0883073898013001051. [PMID: 9796747] - M H Nelson, A K Birnbaum, P J Nyhus, R P Remmel. A capillary GC-MS method for analysis of phenytoin and [13C3]-phenytoin from plasma obtained from pulse dose pharmacokinetic studies.
Journal of pharmaceutical and biomedical analysis.
1998 Sep; 17(8):1311-23. doi:
10.1016/s0731-7085(98)00018-1. [PMID: 9800650] - A R Kugler, T M Annesley, G D Nordblom, J R Koup, S C Olson. Cross-reactivity of fosphenytoin in two human plasma phenytoin immunoassays.
Clinical chemistry.
1998 Jul; 44(7):1474-80. doi:
10.1093/clinchem/44.7.1474. [PMID: 9665426] - W Löscher, E Reissmüller, U Ebert. Anticonvulsant effect of fosphenytoin in amygdala-kindled rats: comparison with phenytoin.
Epilepsy research.
1998 Mar; 30(1):69-76. doi:
10.1016/s0920-1211(97)00098-3. [PMID: 9551846] - M J Cwik, M Liang, K Deyo, C Andrews, J Fischer. Simultaneous rapid high-performance liquid chromatographic determination of phenytoin and its prodrug, fosphenytoin in human plasma and ultrafiltrate.
Journal of chromatography. B, Biomedical sciences and applications.
1997 Jun; 693(2):407-14. doi:
10.1016/s0378-4347(97)00057-1. [PMID: 9210446] - L S Fierro, D H Savulich, D A Benezra. Safety of fosphenytoin sodium.
American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
1996 Nov; 53(22):2707-12. doi:
10.1093/ajhp/53.22.2707. [PMID: 8931812] - H Qi, G C Newman. Phenytoin-induced hyperglycaemia may confound rat cerebroprotection models.
Clinical and experimental pharmacology & physiology.
1996 Oct; 23(10-11):893-7. doi:
10.1111/j.1440-1681.1996.tb01140.x. [PMID: 8911732] - B J Wilder, K Campbell, R E Ramsay, W R Garnett, J M Pellock, S A Henkin, A R Kugler. Safety and tolerance of multiple doses of intramuscular fosphenytoin substituted for oral phenytoin in epilepsy or neurosurgery.
Archives of neurology.
1996 Aug; 53(8):764-8. doi:
10.1001/archneur.1996.00550080082016. [PMID: 8759983] - B A Boucher, C A Feler, J C Dean, D D Michie, B K Tipton, K R Smith, R E Kramer, B Young, B R Parks, A R Kugler. The safety, tolerability, and pharmacokinetics of fosphenytoin after intramuscular and intravenous administration in neurosurgery patients.
Pharmacotherapy.
1996 Jul; 16(4):638-45. doi:
NULL. [PMID: 8840370] - T R Browne, A R Kugler, M A Eldon. Pharmacology and pharmacokinetics of fosphenytoin.
Neurology.
1996 Jun; 46(6 Suppl 1):S3-7. doi:
10.1212/wnl.46.6_suppl_1.3s. [PMID: 8649612] - R E Ramsay, J DeToledo. Intravenous administration of fosphenytoin: options for the management of seizures.
Neurology.
1996 Jun; 46(6 Suppl 1):S17-9. doi:
10.1212/wnl.46.6_suppl_1.17s. [PMID: 8649609] - B M Uthman, B J Wilder, R E Ramsay. Intramuscular use of fosphenytoin: an overview.
Neurology.
1996 Jun; 46(6 Suppl 1):S24-8. doi:
10.1212/wnl.46.6_suppl_1.24s. [PMID: 8649611] - C M Lai, P Moore, C Y Quon. Binding of fosphenytoin, phosphate ester pro drug of phenytoin, to human serum proteins and competitive binding with carbamazepine, diazepam, phenobarbital, phenylbutazone, phenytoin, valproic acid or warfarin.
Research communications in molecular pathology and pharmacology.
1995 Apr; 88(1):51-62. doi:
. [PMID: 7620838] - T R Browne, G K Szabo, C McEntegart, J E Evans, B A Evans, J J Miceli, C Quon, C L Dougherty, J Kres, H Davoudi. Bioavailability studies of drugs with nonlinear pharmacokinetics: II. Absolute bioavailability of intravenous phenytoin prodrug at therapeutic phenytoin serum concentrations determined by double-stable isotope technique.
Journal of clinical pharmacology.
1993 Jan; 33(1):89-94. doi:
10.1002/j.1552-4604.1993.tb03910.x. [PMID: 8429121] - B D Jamerson, K H Donn, G E Dukes, J A Messenheimer, K L Brouwer, J R Powell. Absolute bioavailability of phenytoin after 3-phosphoryloxymethyl phenytoin disodium (ACC-9653) administration to humans.
Epilepsia.
1990 Sep; 31(5):592-7. doi:
10.1111/j.1528-1157.1990.tb06111.x. [PMID: 2401249] - N Y Walton, D M Treiman. Efficacy of ACC-9653 (a phenytoin prodrug) in experimental status epilepticus in the rat.
Epilepsy research.
1990 Mar; 5(2):165-8. doi:
10.1016/0920-1211(90)90034-s. [PMID: 2328717] - B A Boucher, A M Bombassaro, S N Rasmussen, C B Watridge, R Achari, P Turlapaty. Phenytoin prodrug 3-phosphoryloxymethyl phenytoin (ACC-9653): pharmacokinetics in patients following intravenous and intramuscular administration.
Journal of pharmaceutical sciences.
1989 Nov; 78(11):929-32. doi:
10.1002/jps.2600781110. [PMID: 2621577] - T R Browne, H Davoudi, K H Donn, C L Dougherty, G E Dukes, B Evans, J E Evans, B Jamerson, J Kres, C M McEntegart. Bioavailability of ACC-9653 (phenytoin prodrug).
Epilepsia.
1989; 30 Suppl 2(?):S27-32. doi:
10.1111/j.1528-1157.1989.tb05822.x. [PMID: 2670536] - I E Leppik, R Boucher, B J Wilder, V S Murthy, C A Rask, C Watridge, N M Graves, R J Rangel, P Turlapaty. Phenytoin prodrug: preclinical and clinical studies.
Epilepsia.
1989; 30 Suppl 2(?):S22-6. doi:
10.1111/j.1528-1157.1989.tb05821.x. [PMID: 2670535] - N Gerber, D C Mays, K H Donn, A Laddu, R M Guthrie, P Turlapaty, C Y Quon, W K Rivenburg. Safety, tolerance and pharmacokinetics of intravenous doses of the phosphate ester of 3-hydroxymethyl-5,5-diphenylhydantoin: a new prodrug of phenytoin.
Journal of clinical pharmacology.
1988 Nov; 28(11):1023-32. doi:
10.1002/j.1552-4604.1988.tb03124.x. [PMID: 3243914] - S A Varia, V J Stella. Phenytoin prodrugs V: In vivo evaluation of some water-soluble phenytoin prodrugs in dogs.
Journal of pharmaceutical sciences.
1984 Aug; 73(8):1080-7. doi:
10.1002/jps.2600730814. [PMID: 6548519]